Brookline Capital Acquisition II, a blank check company formed by Brookline Capital Markets targeting healthcare and defense, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Brookline Capital Acquisition II is led by Chairman Samuel Wertheimer, a Senior Scientific Advisor at Brookline Capital Markets. Management’s previous SPAC, Brookline Capital Acquisition, merged with Apexigen (formerly Nasdaq: APGN) in 2022, which was delisted after being acquired by Pyxis Oncology in 2023.
Read the full article: SPAC Brookline Capital Acquisition II Files for a $100M IPO, Targeting Healthcare //
Source: https://www.renaissancecapital.com/IPO-Center/News/115720/SPAC-Brookline-Capital-Acquisition-II-files-for-a-$100-million-IPO-targetin